<DOC>
	<DOCNO>NCT01206764</DOCNO>
	<brief_summary>Renal cell carcinoma ( RCC ) account 200,000 new case cancer 100,000 cancer death annually World ( Ferlay , et al. , 2004 ) . It estimate 15,000 new case RCC region exclude Americas , European Union Japan . Renal cell carcinoma arise proximal tubal epithelium common male female overall lifetime risk 1 75 median age diagnosis 65 year . Everolimus ( Certican® ) approve since 2003 60 country prevention organ rejection patient renal cardiac transplantation . Everolimus ( RAD001 ) derivative rapamycin , act signal transduction inhibitor . It target mTOR , key protein kinase regulate cell growth , proliferation , survival . The mTOR pathway activity modulate phosphatidylinositol-3-kinase ( PI3K ) /protein kinase B AKT ( AKT ) pathway , pathway know deregulate numerous human cancer . RAD001 ( Afinitor® ) investigate anticancer agent base potential act : - directly tumor cell inhibit tumor cell growth proliferation ; - indirectly inhibit angiogenesis lead reduced tumor vascularity ( via potent inhibition tumor cell hypoxia-inducible factor 1 ( HIF-1 ) activity , VEGF production , VEGF-induced proliferation endothelial cell ) . Primary : To evaluate PFS rate time . Secondary : - To evaluate disease control rate ( stable disease [ SD ] + partial response [ PR ] + complete response [ CR ] ) ; - To evaluate objective response rate ( ORR ; ORR = CR + PR ) duration ; - To describe safety profile RAD001 .</brief_summary>
	<brief_title>A Trial Everolimis Patients With Advanced Renal Cell Carcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients may enter study meet follow criterion : Age ≥18 year old ; Patients advance renal cell carcinoma confirm clear nonclear cell histology , without nephrectomy , MSKCC prognosis ; Prior cytokine therapy permit ; Patients least one measurable lesion baseline per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . If skin lesion report target lesion , must document ( baseline every physical exam ) use color photography measure device ( caliper ) clear focus allow size lesion ( ) determine photograph ; Life expectancy ≥3 month . Life expectancy judge relation determine patient eligibility factor laboratory result , Karnofsky Performance Status , etc . ; Patients Karnofsky Performance Status ≥70 % ; Adequate bone marrow function show : absolute neutrophil count ( ANC ) ≥1.5 x 109/L , platelet ≥100 x 109/L , hemoglobin ( Hb ) &gt; 9 g/dL ; Adequate liver function : serum bilirubin ≤1.5 x upper limit normal ( ULN ) , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) ≤2.5 x ULN ; Adequate renal function : serum creatinine ≤1.5 x ULN ; Females childbearing potential must negative serum urine pregnancy test 7 day prior administration study treatment start ; Patients give write informed consent obtain accord local guideline . Patients may enter study meet follow criterion : Patients within 2 week postminor surgery ( e.g. , herniorrhaphy ) , 4 week postmajor surgery ( e.g. , intrathoracic , intraabdominal , intrapelvic ) avoid wound heal complication . Percutaneous biopsy require wait time prior study entry ; Patients recent history hemoptysis , ≥0.5 teaspoon red blood ; Patients receive prior systemic treatment metastatic RCC cytokine therapy ; Patients receive prior therapy VEGF pathway inhibitor , sunitinib , sorafenib , bevacizumab ; Patients previously receive mTOR inhibitor ( sirolimus , temsirolimus , everolimus , deferolimus ) ; History clinical evidence central nervous system ( CNS ) metastases . Note : Subjects previouslytreated CNS metastasis ( surgery ± radiotherapy , radiosurgery , gamma knife ) meet 3 follow criterion eligible : Are asymptomatic ; Have evidence active CNS metastasis ≥6 month prior enrollment ; Have requirement steroid enzymeinducing anticonvulsant ( EIAC ) ; • Clinically significant gastrointestinal abnormality include , limited : Malabsorption syndrome ; Major resection stomach small bowel could affect absorption study drug ; Active peptic ulcer disease ; Inflammatory bowel disease ; Ulcerative colitis , gastrointestinal condition increase risk perforation ; History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment ; Patients receive chronic systemic treatment corticosteroid ( dose ≥10 mg/day methylprednisone equivalent ) another immunesuppressive agent . Inhaled topical steroid acceptable , well opotherapy bilateral adrenal gland removal ; Patients know history human immunodeficiency virus seropositivity ; Patients autoimmune hepatitis ; Patients active , bleeding diathesis . Patients may use coumadin heparin preparation ; Patients severe and/or uncontrolled medical condition condition could affect participation study ; Patients history another primary malignancy ≤3 year , exception nonmelanoma skin cancer carcinoma situ uterine ; Female patient pregnant breastfeeding , adult reproductive potential use effective birth control method . If barrier contraceptive use , must continue throughout study sex . Oral contraceptive acceptable ; Patients use investigational agent receive investigational drug ≤4 week prior study treatment start ; Patients unwilling unable comply protocol . Other protocoldefined inclusion/exclusion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>RCC ,</keyword>
	<keyword>mTOR pathway ,</keyword>
	<keyword>angiogenesis ,</keyword>
	<keyword>PFS ,</keyword>
	<keyword>partial response [ PR ] + complete response [ CR ] )</keyword>
	<keyword>metastatic recurrent renal cell carcinoma</keyword>
	<keyword>metastatic unresectable renal cell carcinoma</keyword>
</DOC>